Literature DB >> 14747388

The number, quality, and coverage of randomized controlled trials in nephrology.

Giovanni F M Strippoli1, Jonathan C Craig, Francesco P Schena.   

Abstract

Randomized controlled trials (RCT) are the optimal study design to answer intervention questions. The authors evaluated the number, quality, and coverage of RCT in nephrology. MEDLINE was searched using the relevant medical subject headings for nephrology and 12 major specialties in internal medicine, limited by "randomized controlled trial" as a publication type. A random selection of 160 RCT in nephrology (40 for each decade) published since 1966 and an additional 270 RCT from ongoing or published Cochrane systematic reviews in various areas of nephrology, dialysis, and transplantation were evaluated for quality of reporting using standard criteria. The number of RCT published in nephrology from 1966 to 2002 (2779) is fewer than all other specialties of internal medicine (range: 5335 in hematology to 27109 in cardiology) with the proportion of all citations which are RCT being the third lowest (1.15%). There has been an increase in both indices from 1966 to 1996, but not at a greater rate than other specialties, and there has been no increase over the past 5 yr. Some areas of nephrology, in particular glomerulonephritis, are clear outliers with very low numbers of RCT to guide clinical decision-making. Overall the quality of RCT reporting in nephrology is low and has not improved over the past 30 yr with unclear allocation concealment (89%), lack of reported blinding of outcome assessors (92%), and failure to perform "intention-to-treat analysis" (50%) particularly frequent. The challenges of improving the quality and quantity of trials in nephrology are substantial, but they can be overcome by using standard guidelines and checklists for trial reporting, greater attention to the trial methods and not just the results, involving experts in trial design and reporting, multicenter collaboration, and larger and simpler trials.

Entities:  

Mesh:

Year:  2004        PMID: 14747388     DOI: 10.1097/01.asn.0000100125.21491.46

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  92 in total

1.  Comparative effectiveness research and the psychology of medical practice: the vicissitudes of knowledge implementation.

Authors:  Jerome P Kassirer; John B Wong
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 2.  Ethical Issues in Pragmatic Cluster-Randomized Trials in Dialysis Facilities.

Authors:  Cory E Goldstein; Charles Weijer; Monica Taljaard; Ahmed A Al-Jaishi; Erika Basile; Jamie Brehaut; Charles L Cook; Jeremy M Grimshaw; Eduardo Lacson; Craig Lindsay; Meg Jardine; Laura M Dember; Amit X Garg
Journal:  Am J Kidney Dis       Date:  2019-06-19       Impact factor: 8.860

3.  Trends in the methodological quality of published randomized controlled trials on antibacterial agents.

Authors:  Matthew E Falagas; Eleni I Pitsouni; Ioannis A Bliziotis
Journal:  Br J Clin Pharmacol       Date:  2008-02-15       Impact factor: 4.335

4.  Novel therapeutic approaches to chronic kidney disease.

Authors:  Neeraj Dhaun; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

Review 5.  Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis.

Authors:  Min Jun; Tanvir Chowdhury Turin; Mark Woodward; Vlado Perkovic; Hiddo J Lambers Heerspink; Braden J Manns; Marcello Tonelli; Brenda R Hemmelgarn
Journal:  J Am Soc Nephrol       Date:  2015-01-02       Impact factor: 10.121

6.  Quantity and Reporting Quality of Kidney Research.

Authors:  Markos Kyriakos Tomidis Chatzimanouil; Louise Wilkens; Hans-Joachim Anders
Journal:  J Am Soc Nephrol       Date:  2018-12-13       Impact factor: 10.121

7.  Complementary Initiatives from the NIDDK to Advance Kidney Health.

Authors:  Jenna M Norton; Christian J Ketchum; Andrew S Narva; Robert A Star; Griffin P Rodgers
Journal:  Clin J Am Soc Nephrol       Date:  2017-07-17       Impact factor: 8.237

8.  Drugs and trials: lessons from Plato.

Authors:  Howard Trachtman
Journal:  Clin Ther       Date:  2013-04-13       Impact factor: 3.393

Review 9.  Kidney disease: improving global outcomes.

Authors:  Kai-Uwe Eckardt; Bertram L Kasiske
Journal:  Nat Rev Nephrol       Date:  2009-09-29       Impact factor: 28.314

Review 10.  Reporting randomised clinical trials of analgesics after traumatic or orthopaedic surgery is inadequate: a systematic review.

Authors:  Eva Montané; Antoni Vallano; Xavier Vidal; Cristina Aguilera; Joan-Ramon Laporte
Journal:  BMC Clin Pharmacol       Date:  2010-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.